JP2023553490A5 - - Google Patents
Info
- Publication number
- JP2023553490A5 JP2023553490A5 JP2023536049A JP2023536049A JP2023553490A5 JP 2023553490 A5 JP2023553490 A5 JP 2023553490A5 JP 2023536049 A JP2023536049 A JP 2023536049A JP 2023536049 A JP2023536049 A JP 2023536049A JP 2023553490 A5 JP2023553490 A5 JP 2023553490A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- expression
- repressor
- expression repressor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125833P | 2020-12-15 | 2020-12-15 | |
| US63/125,833 | 2020-12-15 | ||
| US202163137097P | 2021-01-13 | 2021-01-13 | |
| US63/137,097 | 2021-01-13 | ||
| US202163212991P | 2021-06-21 | 2021-06-21 | |
| US63/212,991 | 2021-06-21 | ||
| US202163281022P | 2021-11-18 | 2021-11-18 | |
| US63/281,022 | 2021-11-18 | ||
| PCT/US2021/010059 WO2022132195A2 (en) | 2020-12-15 | 2021-12-15 | Compositions and methods for modulation myc expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553490A JP2023553490A (ja) | 2023-12-21 |
| JP2023553490A5 true JP2023553490A5 (enExample) | 2024-12-23 |
Family
ID=82060102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536049A Pending JP2023553490A (ja) | 2020-12-15 | 2021-12-15 | Ｍｙｃ発現を調節するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240132559A1 (enExample) |
| EP (1) | EP4262849A4 (enExample) |
| JP (1) | JP2023553490A (enExample) |
| KR (1) | KR20230120138A (enExample) |
| AU (1) | AU2021401231A1 (enExample) |
| CA (1) | CA3205133A1 (enExample) |
| MX (1) | MX2023007116A (enExample) |
| WO (1) | WO2022132195A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049075A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| CN115192714B (zh) * | 2022-07-08 | 2024-09-17 | 沈阳药科大学 | Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| JP2026518711A (ja) | 2023-05-16 | 2026-06-09 | フラッグシップ ラブズ １１４， インコーポレイテッド | 標的遺伝子のメチル化を調節するための方法及び組成物 |
| EP4716741A2 (en) * | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025144907A1 (en) * | 2023-12-27 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Kinase inhibitors and particles comprising myc modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011972A1 (en) * | 1995-09-28 | 1997-04-03 | The Trustees Of Columbia University In The City Of New York | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| GB201119904D0 (en) * | 2011-11-17 | 2011-12-28 | Univ Vilnius | Analysis of methylation sites |
| WO2016103233A2 (en) * | 2014-12-24 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Systems and methods for genome modification and regulation |
| KR101900278B1 (ko) * | 2016-04-18 | 2018-09-19 | 건국대학교 글로컬산학협력단 | Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법 |
| WO2018111944A1 (en) * | 2016-12-12 | 2018-06-21 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| WO2018183808A1 (en) * | 2017-03-31 | 2018-10-04 | Agenovir Corporation | Antiviral therapeutic |
| US20190233805A1 (en) * | 2017-10-04 | 2019-08-01 | The Regents Of The University Of California | Targetable proteins for epigenetic modification and methods for use thereof |
| EP3867368A4 (en) * | 2018-10-15 | 2022-08-10 | Flagship Pioneering Innovations V, Inc. | DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES |
| US11866469B2 (en) * | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
-
2021
- 2021-12-15 WO PCT/US2021/010059 patent/WO2022132195A2/en not_active Ceased
- 2021-12-15 EP EP21907332.7A patent/EP4262849A4/en active Pending
- 2021-12-15 MX MX2023007116A patent/MX2023007116A/es unknown
- 2021-12-15 KR KR1020237024060A patent/KR20230120138A/ko active Pending
- 2021-12-15 AU AU2021401231A patent/AU2021401231A1/en active Pending
- 2021-12-15 US US18/257,483 patent/US20240132559A1/en active Pending
- 2021-12-15 JP JP2023536049A patent/JP2023553490A/ja active Pending
- 2021-12-15 CA CA3205133A patent/CA3205133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matchett et al. | Ran GTPase in nuclear envelope formation and cancer metastasis | |
| US10071129B2 (en) | Method for identifying bromodomain inhibitors | |
| CN110917352A (zh) | Rock抑制剂在肿瘤免疫治疗中的新用法 | |
| CN108486247A (zh) | piRNA-54265在结直肠癌的诊治和预后评价方面的应用 | |
| CN101528925A (zh) | 双链断裂诱饵及其应用 | |
| AU2024259837B2 (en) | ADP-ribose binding peptide having anticancer activity and use thereof | |
| Larsen et al. | From DNA damage to G~ 2 arrest: The many roles of topoisomerase II | |
| Graziano et al. | Mechanisms of oncogene-induced genomic instability | |
| Wang et al. | Cancer‐derived IgG involved in cisplatin resistance through PTP‐BAS/Src/PDK1/AKT signaling pathway | |
| CN111671904A (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| KR20190040824A (ko) | CRISP/Cas 시스템에 사용하기 위한 융합 단백질, 그를 포함하는 복합체 및 그의 용도 | |
| CN108410878B (zh) | 一种lrpprc特异性核酸适配体及其应用 | |
| KR102618932B1 (ko) | Runx3 단백질 및 CDK4 억제제 또는 mTOR 억제제 병행 투여를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물 | |
| Zhang et al. | BRD4 protein as a target for lung cancer and hematological cancer therapy: a review | |
| KR102576855B1 (ko) | Tsp1을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 | |
| Fu et al. | ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer | |
| US9145554B2 (en) | Cancer therapy method | |
| US20220064238A1 (en) | Methods And Compositions For Modifying Transcription Factor Activity by Targeting The Human Mediator Complex Using Cell Penetrating Memetic Peptides And Methods of Treating Cancer Using The Same | |
| TW201628630A (zh) | 細胞死亡誘導劑、細胞增殖抑制劑及起因於細胞增殖異常之疾病治療用醫藥組合物 | |
| US20250066420A1 (en) | Pd-l1 inhibitory peptide for cancer immunotherapy | |
| US20190030126A1 (en) | Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors | |
| KR20260074247A (ko) | 바이오마커로서의 drg2의 용도 | |
| HK40130287A (en) | Lincrna-p21 and use thereof | |
| CN117801064A (zh) | 一种多肽、药物和用途 | |
| US20210401931A1 (en) | Methods and materials for treating cancer |